GSK3884464

GSK3884464 is an orally administered small molecule drug developed by GSK (formerly GlaxoSmithKline) for the treatment of heart failure, specifically targeting heart failure with reduced ejection fraction (HFrEF)[1][2][3]. The exact mechanism of action has not been publicly disclosed and remains undefined[1][3][7]. In clinical studies, the drug demonstrated rapid absorption and dose-dependent target engagement as measured by increases in NQO1 gene expression in whole blood following administration[2]. However, development was halted after a phase I trial due to elevated liver enzymes observed in some participants[2].